Swiss Life Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$66.4M Buy
525,655
+136,175
+35% +$17.9M 0.28% 72
2026
Q1
$54.3M Buy
389,480
+18,110
+5% +$2.54M 0.27% 72
2025
Q4
$45.6M Sell
371,370
-197,901
-35% -$24.1M 0.23% 84
2025
Q3
$63.2M Buy
569,271
+31,807
+6% +$3.62M 0.33% 61
2025
Q2
$59.6M Sell
537,464
-21,415
-4% -$2.28M 0.35% 62
2025
Q1
$62.6M Buy
558,879
+19,353
+4% +$2M 0.46% 45
2024
Q4
$49.8M Buy
539,526
+36,973
+7% +$3.33M 0.37% 56
2024
Q3
$42.1M Buy
502,553
+68,068
+16% +$5.19M 0.48% 41
2024
Q2
$29.8M Sell
434,485
-22,096
-5% -$1.47M 0.35% 60
2024
Q1
$33.4M Buy
456,581
+1,403
+0.3% +$108K 0.46% 47
2023
Q4
$36.9M Sell
455,178
-65,096
-13% -$5.07M 0.44% 37
2023
Q3
$39M Buy
520,274
+19,858
+4% +$1.53M 0.6% 27
2023
Q2
$38.6M Sell
500,416
-14,981
-3% -$1.19M 0.57% 28
2023
Q1
$42.8M Buy
515,397
+136,143
+36% +$11.3M 0.64% 25
2022
Q4
$32.6M Sell
379,254
-40,490
-10% -$3.21M 0.54% 33
2022
Q3
$25.9M Sell
419,744
-43,494
-9% -$2.74M 0.45% 38
2022
Q2
$28.7M Buy
463,238
+47,284
+11% +$2.93M 0.46% 37
2022
Q1
$24.7M Buy
415,954
+10,751
+3% +$687K 0.35% 58
2021
Q4
$29.4M Buy
405,203
+152,889
+61% +$10.5M 0.38% 54
2021
Q3
$17.6M Sell
252,314
-45,056
-15% -$3.17M 0.24% 94
2021
Q2
$15.6M Sell
297,370
-4,558
-2% -$304K 0.16% 118
2021
Q1
$19.5M Buy
301,928
+7,105
+2% +$458K 0.28% 80
2020
Q4
$17.2M Buy
294,823
+234,377
+388% +$14.1M 0.25% 89
2020
Q3
$3.82M Sell
60,446
-92,078
-60% -$6.39M 0.06% 227
2020
Q2
$11.7M Buy
152,524
+63,198
+71% +$4.84M 0.19% 108
2020
Q1
$6.68M Buy
89,326
+41,561
+87% +$2.87M 0.13% 138
2019
Q4
$3.1M Sell
47,765
-73,662
-61% -$4.8M 0.06% 257
2019
Q3
$7.7M Sell
121,427
-21,141
-15% -$1.38M 0.1% 149
2019
Q2
$9.62M Buy
142,568
+54,238
+61% +$3.57M 0.12% 131
2019
Q1
$5.74M Sell
88,330
-468,140
-84% -$31.1M 0.07% 169
2018
Q4
$34.8M Sell
556,470
-292,057
-34% -$20.4M 0.71% 35
2018
Q3
$65.5M Buy
848,527
+440,262
+108% +$33.3M 0.88% 23
2018
Q2
$28.9M Sell
408,265
-299,355
-42% -$21.1M 0.43% 62
2018
Q1
$53.3M Buy
707,620
+414,259
+141% +$32.9M 0.93% 18
2017
Q4
$21M Buy
293,361
+68,784
+31% +$5.22M 0.47% 74
2017
Q3
$18.2M Buy
224,577
+5,675
+3% +$434K 0.49% 65
2017
Q2
$15.5M Buy
218,902
+7,391
+3% +$492K 0.4% 70
2017
Q1
$14.4M Buy
211,511
+128,295
+154% +$9.02M 0.39% 74
2016
Q4
$5.96M Sell
83,216
-99,656
-54% -$7.41M 0.2% 97
2016
Q3
$14.5M Buy
182,872
+487
+0.3% +$39.6K 0.49% 55
2016
Q2
$15.2M Buy
182,385
+31,362
+21% +$2.78M 0.62% 44
2016
Q1
$13.9M Buy
151,023
+9,691
+7% +$874K 0.59% 43
2015
Q4
$14.3M Buy
141,332
+7,519
+6% +$782K 0.64% 41
2015
Q3
$13.1M Buy
133,813
+9,353
+8% +$1.04M 0.64% 37
2015
Q2
$14.6M Sell
124,460
-2,944
-2% -$322K 0.51% 29
2015
Q1
$12.5M Buy
+127,404
New +$12.9M 0.5% 40

Other funds holding GILD

Swiss Life Asset Management's GILD Position: Q2 2026 in Review

Swiss Life Asset Management increased its Gilead Sciences (GILD) stake by 35% in Q2 2026, buying an estimated $17.9M and bringing the position to 525,655 shares worth $66.4M. The position accounts for 0.28% of the portfolio, ranked #72.

Swiss Life Asset Management first reported a position in GILD in Q1 2015 and has held it in 46 quarters since. 1,671 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Swiss Life Asset Management held 525,655 shares of Gilead Sciences worth $66.4M as of Q2 2026.
  • Swiss Life Asset Management bought 136,175 Gilead Sciences shares in Q2 2026, an estimated $17.9M.
  • Gilead Sciences made up 0.28% of Swiss Life Asset Management's portfolio in Q2 2026, its #72 holding.
  • Swiss Life Asset Management first reported a position in Gilead Sciences in Q1 2015 and has held it in 46 quarters since.
  • 1,671 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.